W-2451 (NSC 294839) is a selective serotonin 5-HT2 receptor antagonist. W-2451 is promising for research of neurological disorders.

VU0631019 is a potent antagonist of 5-HT2B, with the IC50 of 29 nM. VU0631019 is predicted to have very limited potential for brain penetration in human subjects, as is predicted to be substrates for P-gp-mediated efflux in humans.

VU0530244 is a potent antagonist of 5-HT2B, with the IC50 of 17.3 nM. VU0530244 is predicted to have very limited potential for brain penetration in human subjects, as is predicted to be substrates for P-gp-mediated efflux in humans.

Trelanserin (SL-650472) is a 5-HT receptor antagonist and also an effective in vitro smooth muscle contraction antagonist, competing against the contractions induced by sumatriptan with a pA2 of 8.17±0.36.

THRX-194556 is a 5-HT4 receptor agonist. THRX-194556 can be used to study gastrointestinal functional disorders and Alzheimer’s disease.

Tenilapine displays potent inverse agonist activity at rat and human 5-HT(2C) receptors.

Serotonin hydrogen maleate is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrogen maleate is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .

SAM-315 (WAY-255315) is a potent antagonist of 5-Hydroxytryptamine-6, with Ki and IC50 of 1.1 nM and 4.6 nM, respectively. SAM-315 significantly increases acetylcholine and glutamate release in hippocampus of the brain.

RS 67506 hydrochloride is a 5-HT4 receptor agonist. The pKi value of RS 67506 hydrochloride for 5-HT4 in guinea pig striatum is 8.8. RS 67506 hydrochloride can be used in neuro-related research.

Ro4368554 is a brain-penetrant and selective 5-HT6 antagonist that reverses memory deficits induced by scopolamine and tryptophan depletion. Ro4368554 can be utilized in research related to memory deficits.

Quetiapine sulfone is a main metabolite of Quetiapine, and through the 15-lipoxygenase-1 pathway.

PUC-55 is a 5-HT6R antagonist with a Ki of 37.5 nM that induces neuronal autophagy by inhibiting the mTOR pathway. It holds potential for research in the field of neurological disorders.

PUC-10 is a 5-HT6 receptor antagonist with a Ki of 14.6 nM and an IC50 of 32 nM. In silico predictions suggest that PUC-10 is orally active and can cross the blood-brain barrier. PUC-10 can induce autophagy in SH-SY5Y cells by inhibiting the mTOR pathway. PUC-10 can be used in the research of neurological disorders.

p-MPPF is a selective 5-HT antagonist that dose-dependently antagonizes the reduction of phosphorylated Erk1/2 levels in the hippocampus induced by 8-OH-DPAT. Aripiprazole N-oxide is formed from aripiprazole by the cytochrome P450 (CYP) isoforms CYP2D6 and CYP3A4.

Pellotine is an alkaloid that can be isolated from Lophophora. Pellotine is the inverse agonist for 5-HT7 receptor with an EC50 of 291 nM. Pellotine exhibits good affinity to 5-HT1DR and 5-HT6R with Ki of 117 nM and 170 nM. Pellotine reduces intracellular cAMP levels, thereby reducing neuronal excitability and neurotransmitter release.

Paynantheine is an alkaloid with antinociceptive activity, which is found in Mitragyna speciosa. Paynantheine is also a 5-HT1AR and 5-HT2BR agonist that induces lower lip retraction and antinociception in rats.

Olanzapine ketolactam (compound 1) is the impurity of Olanzapine. Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT

NLX-266 is an orally active ERK1/2-biased 5-HT1A receptor agonist. NLX-266 can be used in the study of Parkinson's disease.

N-Desmethyl asenapine is a metabolite of Asenapine.

MRS8209 is the antagonist for serotonin receptor with a Ki of 4.27 nM for 5-HT2BR. MRS8209 exhibits protective effect on pressure at airway opening (PAO), and can be used in research of pulmonary fibrosis.

Mirtazapine N-oxide is a metabolite of Mirtazapine.

Methamnetamine (PAL-1046) hydrochloride is an amphetamine-based psychoactive substance. Methamnetamine hydrochloride causes excessive release of serotonin.

LY-272015 is an orally active, specific 5-HT2B receptor antagonist. LY-272015 completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86. LY-272015 is antihypertensive in Deoxycorticosterone Acetate (DOCA)-salt-hypertensive rats.

Jimscaline (compound R-(-)2) is a 5-HT2A agonist and mescaline analogue that can be utilized in neurological research.

IHCH-7086 is a β-arrestin-biased 5-HT2A serotonin receptor agonist (Ki: 12.59 nM). IHCH-7086 recruits β-arrestin through activation of 5-HT2A receptors, thereby removing hallucinogenic activity. IHCH-7086 improves depression-like behavior in mice without hallucinogenic effects.

Hydrodolasetron is a metabolite of Dolasetron. Hydrodolasetron is more potent than Dolasetron in inhibiting nAChR. Hydrodolasetron is a 5-HT(3A)R blocker with an IC50 of 0.29 nM. Hydrodolasetron has antiemetic activity.

Flibanserin hydrochloride (BIMT-17 hydrochloride) is an orally active 5-HT1A receptor agonist and 5-HT2A receptor antagonist with binding affinities Ki of 1 nM and 49 nM, respectively. Flibanserin hydrochloride also binds to dopamine D4 receptors with a Ki of 4-24 nM. Flibanserin hydrochloride has antidepressant and anxiolytic effects and can be used in the study of hypoactive sexual desire disorder (HSDD).

Etoperidone, an antidepressant agent, is an orally active serotonin and nor-adrenaline re-uptake antagonist. Etoperidone shows Kd values of 36 nM, 38 nM, 85 nM, and 570 nM for 5-HT2 receptor, α1-adrenergic receptor, 5-HT1A receptor, and α2-adrenergic receptor, respectively.

Ethylpropyltryptamine (EPT) is a novel orally active psychoactive substance. Ethylpropyltryptamine (EPT) is predicted to be a partial agonist of the 5-HT2A receptor.

ECPLA, a lysergamide lysergic acid diethylamidean (LSD) analog, is a potent 5-HT2A agonist (EC50 of 14.6 nM) for Gq-mediated calcium flux. ECPLA has high affinity for most serotonin receptors, α2-adrenoceptors, and D2-like dopamine receptors.